We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Myhealthchecked Plc | LSE:MHC | London | Ordinary Share | GB00BN7K5L93 | ORD 1.5P |
| Price Change | % Change | Share Price | Shares Traded | Last Trade
|
|
|---|---|---|---|---|---|
| 0.00 | 0.00% | 14.50 | 17,957 | 08:00:14 |
| Bid Price | Offer Price | High Price | Low Price | Open Price | |
|---|---|---|---|---|---|
| 14.00 | 15.00 | 14.50 | 14.50 | 14.50 | |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| Surgical,med Instr,apparatus | 10.98M | -159k | -0.0031 | -46.77 | 7.55M |
| Last Trade Time | Trade Type | Trade Size | Trade Price | Currency |
|---|---|---|---|---|
| 11:02:19 | O | 13 | 14.00 | GBX |
| Date | Time | Source | Headline |
|---|---|---|---|
| 25/4/2025 | 21:39 | ALNC |  TRADING UPDATES: Argentex agrees IFX bid; Marula strikes Botswana deal |
| 25/4/2025 | 07:00 | UK RNS | MyHealthChecked PLC Potential VAT reclaim – update |
| 20/1/2025 | 07:00 | UK RNS | MyHealthChecked PLC Holding(s) in Company |
| 15/1/2025 | 11:11 | UK RNS | MyHealthChecked PLC Holding(s) in Company |
| 14/1/2025 | 16:19 | ALNC | IN BRIEF: MyHealthChecked registers phlebotomy test kits in UK and EU |
| 14/1/2025 | 07:00 | UK RNS | MyHealthChecked PLC Phlebotomy tests registered in the UK and EU |
| 23/12/2024 | 11:56 | UK RNS | MyHealthChecked PLC Exercise of Options |
| 25/11/2024 | 10:11 | UK RNS | MyHealthChecked PLC Holding(s) in Company |
| 01/10/2024 | 11:12 | UK RNS | MyHealthChecked PLC Holding(s) in Company |
| 26/9/2024 | 15:04 | ALNC | EARNINGS AND TRADING: Touchstar mulls strategic options as profit down |
Myhealthchecked (MHC) Share Charts1 Year Myhealthchecked Chart |
|
1 Month Myhealthchecked Chart |
Intraday Myhealthchecked Chart |
| Date | Time | Title | Posts |
|---|---|---|---|
| 25/4/2025 | 07:13 | MyHealthChecked PLC to 100p | 10,416 |
| Trade Time | Trade Price | Trade Size | Trade Value | Trade Type |
|---|
| Top Posts |
|---|
Posted at 26/4/2025 09:20 by Myhealthchecked Daily Update Myhealthchecked Plc is listed in the Surgical,med Instr,apparatus sector of the London Stock Exchange with ticker MHC. The last closing price for Myhealthchecked was 14.50p.Myhealthchecked currently has 52,035,932 shares in issue. The market capitalisation of Myhealthchecked is £7,545,210. Myhealthchecked has a price to earnings ratio (PE ratio) of -46.77. This morning MHC shares opened at 14.50p |
Posted at 31/1/2025 20:02 by tia01 SpacedustI see MHC and ABDX as similar companies to compare although ABDX and MHC are not on the exact same page. Given they are competitors in the LFT tests in Boots etc let’s compare both. ABDX ABDX have a market cap of 15m won £800,000 funding for a project. Going for revenue growth strategy. Raised cash for acquisition etc. MHC Probably 5m cash in Bank 1.6m VAT refund anticipated. New Poc Doc deal worth! New launch of phlebotomy tests! New deal with pharmacy 2U. Awaiting deal with Boots. Newfoundand HIV very positive sales. Increased stores = increased revenue. Focus on digital data. Possible deal to help GPs/NHS lists. 3m from Boots Covid test order! Healthy balance sheet. Controlled wage costs. Little effect from government NI change. Established relationship with Boots. I like and I’m in Both companies but there’s no reason at all why ABDX has a market cap of 15m and MHC only 10m Even based on same market cap MHC should be 30p minimum and possibly more given the balance sheet is healthier and through prudent cost control not needed capital raise. Self funded since the launch years ago is a huge testament to a prudent board. If shares suddenly rose to a decent and reasonable valuation I would be satisfied with a fund raise that help fund any acquisitions. Only if price to around 40-50p level which is justified given pending news. Dividends a bonus but not realistic while we expand range and need capital for reinvestment. |
Posted at 28/1/2025 10:14 by tia01 A dividend is just a dream and to be honest I’m happy to see we have capital for self expansion with dilution.However a dividend of 5% wouldn’t impact the balance sheet and allow long term holders capital to reinvest. I am somewhat confused that MHC didn’t use capital to buy 10% of its stock when the shares fell to all time lows. A resolution was passed a few years back allowing this and if they did they would have made a significant gain and it would have allowed to leverage a rising share price at a later date. Hindsight I guess but knowing the plans it would of been a obvious strategy if I were a board member given your lucky to get 3% on capital sat in the bank |
Posted at 23/1/2025 16:49 by tia01 The shares have held up well considering competition like ABDX falling away.Whilst MHC has cash and prudent ABDX has expanded via revenue growth. Both strategies are good to be fair but MHC are now in a position to create serious revenue growth via its strategy with Boots and pharmacy 2U. It’s clear MHC are aware the government must cut GP waiting lists to install voters confidence which has all but evaporated since the election. The key is nothing goes up in a straight line but while main investors are continuing to support any pullbacks its will become apparent to the MArket Makers this is due a rerate. Nothing is guaranteed but a good update demonstrating Covid revenue is being replaced with growth in new products the markets will truly back the board with a share price rise. I do however see a capital raise if MHC share price was to rise similarly to how TRLS did because it would enable MHC to make strategic acquisitions. I 100% this is the year for MHC and investors and we must be patient and wait for the overdue update. Once again No debt Strong Cash Flow Strong growth in new products. Phlebotomy tests coming Store expansion implemented in 2024. Possible pharmacy first deal with NHS! Corporate contracts Poc doc announcement due Pharmacy 2U Fully funded expansion Only 52m shares, half tied up. Directors eligible to buy after deals and negotiations with Boots completed. So much to be positive about in 2025 |
Posted at 20/1/2025 08:07 by spacedust Mhc is one of those shares were even if they got a 100m pound contract the share price will not go up as much. I've seen this happen with aim shares. But give us a debt laiden trash and you'll see them spike to the moon |
Posted at 19/1/2025 13:59 by tia01 So what can we expect in update!.New products bedding in well. HIV tests selling well. Poc Doc rolling out strategy. Pharmacy 2U sale/plans update News on Boots deal! Strong revenue from Covid to continue self funded growth plan. New products plans. Strong balance sheet. Plans to help cut GP lists using Boots and MHC. Read link attached News that could be significant NHS plans with Boots and MHC however this may need to be finalised. Possible Dividends but doubtful. Any significant rise in share price could lead to an opportunity to raise funds for growth by acquisition route. Overall I expect a positive update and truly expect more large shareholders to take advantage of low Market Cap and well undervalued shares based on fundamentals and strategy. |
Posted at 12/12/2024 12:20 by tia01 I personally can assure you Penny has positive plans. It’s all in the last statement from both Penny and Chairman. I do understand the comments but this is no dead duck. The future of health is in self testing. NHS is definitely in crisis. MHC could easily rocket, fall or do nothing but fact they have guided the company through 4 years since pandemic without raising or diluting is testimony to a prudent management team. Would I like to see more deals!for sure 100% but I’m equally sure one is in the pipeline between Boots and MHC regarding phlebotomy testing as in the Chairman’s statement. Is this a game changer. Absolutely because GPs are overwhelmed and this government wants to cut appointments which cost NHS £50 each. Digital data and self testing go hand in hand so hopefully 2025 will be MHCs year. An update due in January and expect news on this at some point. Inevitably as they move away from Covid testing it will be volatile however deals like the Poc Doc one and HIV tests are proving that MHC can see the direction for growth. Not to forget new online pharmacy deal. We also have a possible 1.6 VAT return coming so maybe MHC are waiting for 2025 to start motoring.More added stores do in store sales should rise over Christmas for new products!. Let’s wish the team well and follow Donald Hamilton as he keeps adding on weakness. |
Posted at 23/11/2024 12:02 by tia01 Penny appears to have got to grips with the manufacturing issues and the restocking in Boots is already underway. Recent price drop in share price is quite healthy as it’s enabled newbie’s to get in or LTHs to top up. I took advantage yesterday with a top up but who knows. I’m in for the long term and journey and if we get the phlebotomy testing deal over the line at Boots this could easily be a multi bagger imo. That’s the key for me as we move away from COVID revenue and we all know the NHS GP situation is getting worse so will Labour do the right thing to solve this by utilising Boots and MHC facilities!. Digital Data is the way forward and MHC is leading the charge so short term pain in pullbacks is long term gain in my eyes.Let’s hope for a little news during Christmas season. Good luck all and remember not many AIM companies still have cash to fund next phase as we do!. |
Posted at 27/10/2024 08:13 by tia01 DualWe know MHC has big plans and clearly in the middle of a deal that is game changing. It will clearly involve Boots and possibly government changes to pharmacy first products available to be used in stores with Boots specialists. The Poc Doc deal is significant also as it will also be sold over the counter or off the shelf. It’s all suggesting that one of the biggest killers in heart disease is a major focus so I personally see heart tests being added to the pharmacy first list. I could be wrong but the government know Boots with MHC tests and digital data can solve the GP appointment problems. Save costs and more efficient and save lives. MHC are focusing on LFT tests IMO which is why they ain’t restocked VITAMIN D tests as no margins in them. I also see a surprise and do wonder if Newfoundland may try a cheap takeover of MHC. They already supply the LFT tests and HIV tests to Boots via MHC!. They are also in many major shops but can’t get in Boots without MHC who have the required approval as you pointed out. Boots is extremely strict which is why it hasn’t stocked the prostrate tests because of the trauma it could cause after a positive test result etc. I think this may change as it’s a big issue. Chris Hoy a true ambassador and legend highlighting the need for more testing is testament to why Boots and MHC need to combine to offer a testing service to the public for NHS patients. Also note many black Caribbean suffer prostrate issues so Boots and MHC could use marketing to target the ethnic communities by highlighting this!. Anyway don’t expect and deal until the new year because of the parties involved and complexity involved. I do anticipate a market campaign to start in November to coincide with the run up to Christmas and the deal that will be announced in the new year hopefully. The focus on Covid revenue has clearly shifted towards testing and the question is can MHC get the revenue breaking deal done without a share dilution required!. I think the answer is 100 YES but equally a VAT refund will ensure the answer is yes. Also note Directors can’t buy until the deal is announced. Once again will Newfoundland be ambitious and smart enough to launch a strike for MHC knowing the potential benefits to both parties. Would MHC make a play for Newfoundland!!!! |
Posted at 11/9/2024 19:02 by tia01 I seriously don’t think Penny believes there’s any money in LFT tests other than Covid ones.Fact is I’m Sure Newfoundland provide MHC with its LFT tests so I guess it’s hard for MHC to compete with them on those tests. MHC clearly focused on phlebotomy testing and I feel a deal with Boots to supply tests for NHS patients. GPs have made the government realise they need a new approach otherwise waiting lists will get even longer and waiting time also. I just feel the share price is suffering as a result of the wait for news. I don’t know what the value of Newfoundland is but could a Merger with MHC really make sense given one is focused more on LFT and the other phlebotomy tests. Time for Penny to deliver something really exciting to share so we can all go to the River Wye to celebrate lol. |
Posted at 27/8/2024 12:32 by muck166 Tia - I don't want to get in a spat with you about valuations, especially on the MHC board. And I am not saying MHC is a bad company - it isn't.Yes, ABDX supplies Boots with some own label tests. In fact, they are exactly the same Chinese tests that MHC also sell through Boots, just in different packaging. And yes, ABDX makes and sells pregnancy tests, as well as other tests. But even a cursory look at its accounts will show you that revenue it makes from total product sales is less than 10% of its total revenue. The bulk of its revenue comes from CDMO/CRO activities on a fee for service model, ie it helps third party lateral flow developers move an idea to a commercial, approved LFT product that can be manufactured at scale and robustly. That is its main business, and its NOT the same as MHC. I don't know why MHC has an MCAP of less than ABDX, but if I were to guess I would say it's because MHC remains heavily reliant on COVID revenue (which is falling) and seems to be stagnating rather than growing, whereas ABDX has growing revenue from a multitude of different customers and streams, as well as some huge potential in its pipe. There are very good reasons why 3 institutional investors took almost all of the recent raise at less than a 10% discount - I assume it's because they see real growth potential in ABDX. Sadly, MHC isn't showing investors anything at the moment. |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
.png){kind=logo}
